Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide Impact on Gastric Emptying in Healthy Subjects
NCT05995704Phase 1Completed
- Sponsor
- VectivBio
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) comparing Apraglutide with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration of Acetaminophen, Time to Maximum Plasma Concentration of Acetaminophen and 3 more. Started Mar 2023; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT05995704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995704.